Harvard Bioscience（HBIO）株式概要ハーバード・バイオサイエンス社は、米州、欧州、中東、アフリカ、アジア、および国際的なライフサイエンス用途の技術、製品、サービスの開発、製造、販売を行っている。 詳細HBIO ファンダメンタル分析スノーフレーク・スコア評価3/6将来の成長0/6過去の実績0/6財務の健全性4/6配当金0/6報酬同業他社や業界と比較して、良好な取引価格 リスク分析US市場と比較した過去 3 か月間の株価の変動現在は利益が出ておらず、今後3年間で利益が出る見込みはない 意味のある時価総額がありません ( $25M )すべてのリスクチェックを見るHBIO Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Analyst Price TargetsAN6.8% undervaluedAnalystConsensusTarget•25d agoDemographic Shifts And NIH Funding Will Unlock Biomedical Potential10504Top Analyst NarrativesHarvard BioscienceANAnalystConsensusTargetBased on Analyst Price TargetsDemographic Shifts And NIH Funding Will Unlock Biomedical PotentialKey Takeaways Strong alignment with biomedical research trends and expanding proprietary technology platforms positions the company well for sustained growth and margin improvement. Enhanced operational efficiency and capital restructuring increase financial flexibility, supporting continued investment in innovation and long-term profitability.View narrativeUS$6FV6.8% 割安 内在価値ディスカウントSet Fair ValueView105users have viewed this narrative0users have liked this narrative0users have commented on this narrative4users have followed this narrative25 days ago author updated this narrativeView all narrativesHarvard Bioscience, Inc. 競合他社BioqualSymbol: OTCPK:BIOQMarket cap: US$31.3mBionano GenomicsSymbol: NasdaqCM:BNGOMarket cap: US$13.8mRadnostixSymbol: OTCPK:INISMarket cap: US$38.7mInotivSymbol: NasdaqCM:NOTVMarket cap: US$9.4m価格と性能株価の高値、安値、推移の概要Harvard Bioscience過去の株価現在の株価US$5.5952週高値US$9.4652週安値US$2.81ベータ1.571ヶ月の変化-18.51%3ヶ月変化-3.79%1年変化66.27%3年間の変化-90.49%5年間の変化-92.01%IPOからの変化-94.68%最新ニュースMajor Estimate Revision • May 19Consensus EPS estimates upgraded to US$1.96 lossThe consensus outlook for fiscal year 2026 has been updated. 2026 losses forecast to reduce from -US$2.45 to -US$1.96 per share. Revenue forecast steady at US$88.6m. Life Sciences industry in the US expected to see average net income growth of 14% next year. Consensus price target of US$6.00 unchanged from last update. Share price fell 7.4% to US$5.01 over the past week.Breakeven Date Change • May 14No longer forecast to breakevenThe 2 analysts covering Harvard Bioscience no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.60m in 2027. New consensus forecast suggests the company will make a loss of US$2.05m in 2027.お知らせ • May 14Harvard Bioscience, Inc. Provides Earnings Guidance for the Second Quarter 2026 and Reaffirms Earnings Guidance for the Full Year 2026Harvard Bioscience, Inc. provided earnings guidance for the second quarter 2026 and reaffirmed earnings guidance for the full year 2026. For the quarter, the company expects Revenue between $20.5 million and $22.5 million. The Company’s second quarter outlook reflects year-over-year revenue growth in the mid-single digit range at the midpoint of guidance. The Company is reaffirming its full-year guidance and anticipates a ramp in revenue in the second half of the year, driven by expected sales growth in higher margin NPI pipeline, which includes products for organoids and electroporation. The Company continues to expect Revenue growth between 2% and 4%.Reported Earnings • May 13First quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2026 results: US$0.77 loss per share (improved from US$11.42 loss in 1Q 2025). Revenue: US$20.8m (down 4.7% from 1Q 2025). Net loss: US$3.42m (loss narrowed 93% from 1Q 2025). Revenue missed analyst estimates by 2.1%. Earnings per share (EPS) exceeded analyst estimates by 19%. Revenue is forecast to grow 1.9% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 19 percentage points per year, which is a significant difference in performance.New Risk • May 12New major risk - Revenue and earnings growthEarnings have declined by 63% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 63% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable next year (US$17m net loss next year). Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (US$30.8m market cap).分析記事 • May 07When Should You Buy Harvard Bioscience, Inc. (NASDAQ:HBIO)?Harvard Bioscience, Inc. ( NASDAQ:HBIO ), is not the largest company out there, but it led the NASDAQCM gainers with a...最新情報をもっと見るRecent updatesMajor Estimate Revision • May 19Consensus EPS estimates upgraded to US$1.96 lossThe consensus outlook for fiscal year 2026 has been updated. 2026 losses forecast to reduce from -US$2.45 to -US$1.96 per share. Revenue forecast steady at US$88.6m. Life Sciences industry in the US expected to see average net income growth of 14% next year. Consensus price target of US$6.00 unchanged from last update. Share price fell 7.4% to US$5.01 over the past week.Breakeven Date Change • May 14No longer forecast to breakevenThe 2 analysts covering Harvard Bioscience no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.60m in 2027. New consensus forecast suggests the company will make a loss of US$2.05m in 2027.お知らせ • May 14Harvard Bioscience, Inc. Provides Earnings Guidance for the Second Quarter 2026 and Reaffirms Earnings Guidance for the Full Year 2026Harvard Bioscience, Inc. provided earnings guidance for the second quarter 2026 and reaffirmed earnings guidance for the full year 2026. For the quarter, the company expects Revenue between $20.5 million and $22.5 million. The Company’s second quarter outlook reflects year-over-year revenue growth in the mid-single digit range at the midpoint of guidance. The Company is reaffirming its full-year guidance and anticipates a ramp in revenue in the second half of the year, driven by expected sales growth in higher margin NPI pipeline, which includes products for organoids and electroporation. The Company continues to expect Revenue growth between 2% and 4%.Reported Earnings • May 13First quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2026 results: US$0.77 loss per share (improved from US$11.42 loss in 1Q 2025). Revenue: US$20.8m (down 4.7% from 1Q 2025). Net loss: US$3.42m (loss narrowed 93% from 1Q 2025). Revenue missed analyst estimates by 2.1%. Earnings per share (EPS) exceeded analyst estimates by 19%. Revenue is forecast to grow 1.9% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 19 percentage points per year, which is a significant difference in performance.New Risk • May 12New major risk - Revenue and earnings growthEarnings have declined by 63% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 63% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable next year (US$17m net loss next year). Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (US$30.8m market cap).分析記事 • May 07When Should You Buy Harvard Bioscience, Inc. (NASDAQ:HBIO)?Harvard Bioscience, Inc. ( NASDAQ:HBIO ), is not the largest company out there, but it led the NASDAQCM gainers with a...ナラティブの更新 • Apr 30HBIO: Reverse Split And 2026 Outlook Will Frame Balanced Risk RewardNarrative Update: Harvard Bioscience Analysts have reset Harvard Bioscience's price target to $6.00 from $0.60, aligning with the recent 1:10 reverse split and updated revenue expectations for 2026. Analyst Commentary Recent commentary around Harvard Bioscience focuses on how the reverse split and updated 2026 revenue expectations feed into valuation and execution risk.Board Change • Apr 29High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. 1 highly experienced director. Lead Independent Director Katherine Eade is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Apr 29Harvard Bioscience, Inc. to Report Q1, 2026 Results on May 12, 2026Harvard Bioscience, Inc. announced that they will report Q1, 2026 results Pre-Market on May 12, 2026お知らせ • Apr 22Harvard Bioscience, Inc., Annual General Meeting, Jun 02, 2026Harvard Bioscience, Inc., Annual General Meeting, Jun 02, 2026.ナラティブの更新 • Apr 12HBIO: Reverse Split And Cost Savings Plan Will Support Future Upside PotentialNarrative Update Analysts have reset their price target on Harvard Bioscience to $6, largely reflecting the recent 1:10 reverse split and the updated revenue expectations in their models. Analyst Commentary Recent research updates on Harvard Bioscience focus on the technical impact of the 1:10 reverse split and revised revenue assumptions, rather than any major shift in the underlying story.ナラティブの更新 • Mar 29HBIO: Reverse Split And Cost Savings Program Will Support Future Recovery PotentialAnalysts have reset their price target for Harvard Bioscience from $0.60 to $6.00, reflecting the recent 1 for 10 reverse split and updated modeling rather than a change in the underlying view on the business. Analyst Commentary Recent research updates on Harvard Bioscience have focused on recalibrating models and targets to reflect the 1 for 10 reverse split and revised revenue expectations, rather than a wholesale change in long term conviction.ナラティブの更新 • Mar 15HBIO: Reset Expectations And Manufacturing Shift Will Set Up Recovery PotentialAnalysts have cut their price target on Harvard Bioscience from $2.00 to $0.60, citing a reduced 2026 revenue estimate of $89.2m versus $95.6m previously and stating that the timing of any recovery is still hard to pinpoint. Analyst Commentary Recent commentary around Harvard Bioscience is focused squarely on the reset to expectations and what it could imply for the share price and business execution over the next few years.お知らせ • Mar 13Harvard Bioscience, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2026Harvard Bioscience, Inc. provided earnings guidance for the First Quarter and Full Year 2026. For the quarter, the Company expects Revenue between $20.0 million and $22.0 million. For the full year, the Company expects Revenue growth between 2% and 4%.お知らせ • Feb 26Harvard Bioscience, Inc. to Report Q4, 2025 Results on Mar 12, 2026Harvard Bioscience, Inc. announced that they will report Q4, 2025 results Pre-Market on Mar 12, 2026お知らせ • Jan 30Harvard Bioscience, Inc. Announces Strategic Consolidation of Manufacturing Operations to Improve Efficiency and Support Long-Term GrowthHarvard Bioscience, Inc. announced a strategic consolidation of its manufacturing operations designed to enhance operational efficiency, strengthen execution, and accelerate cost-savings efforts. The Company will close its manufacturing facility in Holliston, MA and transition U.S. production to its manufacturing hub in Minneapolis, MN. Certain operations will also be relocated to facilities in Germany, Sweden, and the UK, aligning specific product lines with their designated center of excellence and most strategically advantageous logistical location. The Holliston facility will remain operational throughout 2026 to support continuity and customer service. The consolidation is expected to be completed by the first quarter of 2027. The Company has implemented a comprehensive, phased transition plan designed to prevent any disruption to order fulfillment, product quality, and technical support. Transition-related costs are expected to generate incremental operating expenses throughout 2026 and in the first half of 2027. This initiative is expected to result in approximately $3 million in cost savings in 2027, and once fully implemented, approximately $4 million in annual cost savings going forward. The savings include reduced overhead, SKU rationalization, improved asset utilization, and a targeted reconfiguration of the Company's workforce across impacted operations. The Company has also filed a Current Report on Form 8-K with the U.S. Securities and Exchange Commission containing additional details regarding the consolidation of operations.New Risk • Dec 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$15m net loss next year). Market cap is less than US$100m (US$31.2m market cap).お知らせ • Dec 17+ 1 more updateHarvard Bioscience, Inc. announced that it expects to receive $40 million in funding from BroadOak Capital Partners, LLCHarvard Bioscience, Inc. announced that it has entered into an agreement with new lender, BroadOak Capital Partners, LLC to provide a $40 million credit facility comprised of three term loans, all of which will be funded on December 17, 2025. The Loan Agreement provides for the following term loans: (i) a term loan in an aggregate principal amount of $10.0 million (the “Term A Loan”), (ii) a term loan in an aggregate principal amount of $22.5 million (the “Term B Loan”) and (iii) a term loan in an aggregate principal amount of $7.5 million (the “Term C Loan” and, together with the Term A Loan and Term B Loan, the “Term Loans”). The Term A Loan and Term B Loan are senior secured obligations maturing on December 17, 2029.分析記事 • Dec 04Further Upside For Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Could Introduce Price Risks After 27% BounceHarvard Bioscience, Inc. ( NASDAQ:HBIO ) shares have continued their recent momentum with a 27% gain in the last month...お知らせ • Nov 07Harvard Bioscience, Inc. Provides Earnings Guidance for the Fourth Quarter of 2025Harvard Bioscience, Inc. provided earnings guidance for the fourth quarter of 2025. For the quarter, the Company expects revenues of $22.5 million to $24.5 million and gross margin in the 58% to 60% range.Reported Earnings • Nov 07Third quarter 2025 earnings: EPS and revenues exceed analyst expectationsThird quarter 2025 results: US$0.028 loss per share (improved from US$0.11 loss in 3Q 2024). Revenue: US$20.6m (down 6.3% from 3Q 2024). Net loss: US$1.23m (loss narrowed 74% from 3Q 2024). Revenue exceeded analyst estimates by 3.0%. Earnings per share (EPS) also surpassed analyst estimates by 50%. Revenue is forecast to grow 5.0% p.a. on average during the next 2 years, compared to a 6.3% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 53 percentage points per year, which is a significant difference in performance.お知らせ • Oct 30Harvard Bioscience, Inc. to Report Q3, 2025 Results on Nov 06, 2025Harvard Bioscience, Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 06, 2025分析記事 • Oct 20Harvard Bioscience, Inc. (NASDAQ:HBIO) Looks Inexpensive But Perhaps Not Attractive EnoughHarvard Bioscience, Inc.'s ( NASDAQ:HBIO ) price-to-sales (or "P/S") ratio of 0.2x might make it look like a strong buy...Price Target Changed • Oct 06Price target decreased by 33% to US$2.00Down from US$3.00, the current price target is provided by 1 analyst. New target price is 355% above last closing price of US$0.44. Stock is down 82% over the past year. The company is forecast to post a net loss per share of US$1.26 next year compared to a net loss per share of US$0.28 last year.Board Change • Oct 06Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. 1 independent director (4 non-independent directors). Lead Independent Director Katherine Eade is the most experienced director on the board, commencing their role in 2017. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.お知らせ • Oct 04Harvard Bioscience Receives a Notification Letter from the Listing Qualifications Department of the Nasdaq Stock MarketOn October 2, 2025, Harvard Bioscience, Inc., received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it had been granted an additional 180 days, or until March 30, 2026, to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”), based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market with the exception of the bid price requirement, and the Company’s written notice of its intention to cure the deficiency during the second compliance period. In order to be eligible to receive the Second Compliance Period, the Company applied to have its common stock transferred from the Nasdaq Global Market to the Nasdaq Capital Market. In connection with the grant of the Second Compliance Period, the application was approved and the Common Stock will move to the Nasdaq Capital Market effective at the opening of business on October 3, 2025. If at any time before March 30, 2026, the bid price of the Common Stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, the Staff will provide written confirmation that the Company has achieved compliance, subject to the Staff’s discretion to extend the minimum bid price compliance period. If the Company does not regain compliance with the Minimum Bid Price Requirement by the end of the Second Compliance Period, the Common Stock will become subject to delisting. In the event that the Company receives notice that the Common Stock is being delisted, the Nasdaq listing rules permit the Company to appeal a delisting determination by the Staff to a hearings panel. The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Market, and the Company’s Common Stock will continue to be listed and traded under the symbol “HBIO.” The Company intends to continue to monitor the closing bid price of the Common Stock between now and March 30, 2026, and will consider available options to regain compliance with the Minimum Bid Price Requirement, including effecting a reverse stock split, if necessary. However, there can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement or will otherwise be in compliance with other Nasdaq Listing Rules.ナラティブの更新 • Sep 11Demographic Shifts And NIH Funding Will Unlock Biomedical PotentialAnalysts have lowered Harvard Bioscience’s price target from $3.00 to $2.00 due to increased uncertainty around research funding, drug pricing pressures, tariff risks, and a generally more cautious sector outlook. Analyst Commentary Uncertainty surrounding basic research funding potentially impacting sector performance.お知らせ • Sep 09Harvard Bioscience, Inc. Appoints Stephen Denelsky to Board of Directors and as Member of Nominating & Governance Committee, Effective September 5, 2025On September 5, 2025, the Board of Directors of Harvard Bioscience, Inc. appointed Stephen DeNelsky to serve as a member of the Board, effective September 5, 2025. Mr. DeNelsky will serve as a Class I director with a term that will expire at the Company’s 2028 annual meeting of stockholders. Mr. DeNelsky was also appointed to serve as a member of the Nominating & Governance Committee of the Board. Mr. DeNelsky, age 57, is a Managing Director at Oaktree Capital Management, a position he has held since 2022. Mr. DeNelsky was previously a Managing Director at Marathon Asset Management from 2019 to 2022 and President at Life Sciences Alternative Funding from 2011 to 2019. Mr. DeNelsky also currently serves on the board of directors of Visioncare Inc. and previously served on the boards of Integrated Diagnostics and AMICAS, Inc. Mr. DeNelsky possesses thirty years of experience in the research, analysis, and valuation of public and private equities in the healthcare industry and has worked across several major sub-sectors of healthcare, including life sciences, pharmaceuticals, devices and services. Mr. DeNelsky earned his B.A. in Economics from the American University and his M.B.A. from the University of Maryland.分析記事 • Aug 14Harvard Bioscience, Inc. (NASDAQ:HBIO) Just Reported, And Analysts Assigned A US$3.00 Price TargetNasdaqGM:HBIO 1 Year Share Price vs Fair Value Explore Harvard Bioscience's Fair Values from the Community and select...お知らせ • Aug 12Harvard Bioscience, Inc. Provides Earnings Guidance for the Third Quarter Ending September 30, 2025Harvard Bioscience, Inc. provided earnings guidance for the third quarter ending September 30, 2025. For the quarter, the Company expects third quarter 2025 revenues of $19 million to $21 million.分析記事 • Jul 23Does Harvard Bioscience (NASDAQ:HBIO) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...お知らせ • Jul 17+ 3 more updatesHarvard Bioscience, Inc. to Report Q2, 2025 Results on Aug 11, 2025Harvard Bioscience, Inc. announced that they will report Q2, 2025 results on Aug 11, 2025お知らせ • Jun 29Harvard Bioscience, Inc. Provides Non-Compliance UpdateOn June 18, 2025, Harvard Bioscience, Inc. (the Company") notified the Nasdaq Stock Market LLC (Nasdaq") that the Company is not in compliance with the audit committee requirement set in Nasdaq Listing Rule 5605(c)(2)(A) (the Audit Committee Composition Requirement") due to the Company having only two members on the audit committee (the Audit Committee") of its Board of Directors (the Board"). The Company's current failure to comply with the Audit Committee Composition Requirement is due to a vacancy resulting from Alan Edrick's resignation from the Board and the Audit Committee effective June 10, 2025. On June 26, 2025, the Company received a letter from the staff at the Listing Qualifications Department of Nasdaq (the "Staff") notifying the Company that the Staff had determined that the Company no longer complies with the Audit Committee Composition Requirement. The Company intends to regain compliance with Nasdaq Listing Rule 5605(c)(2)(A) by appointing a new Board member who meets the independence requirements under Nasdaq rules and Rule 10A-3(b)(1) under the Securities Exchange Act of 1934, as amended, as expeditiously as practicable. Until such appointment, the Company plans to rely on the cure period set forth in Nasdaq Listing Rule 5605(c)(4), which gives the Company until the earlier of (i) the Company's next annual meeting of stockholders or (ii) one year from Mr. Edrick's resignation, or June 10, 2026 to satisfy the Audit Committee Composition Requirement.お知らせ • Jun 24Harvard Bioscience Receives Nasdaq Non-Compliance Notice Regarding Audit Committee RequirementOn June 18, 2025, Harvard Bioscience, Inc. (the Company") notified the Nasdaq Stock Market LLC (Nasdaq") that the Company is not in compliance with the audit committee requirement set in Nasdaq Listing Rule 5605(c)(2)(A) (the Audit Committee Composition Requirement") due to the Company having only two members on the audit committee (the Audit Committee") of its Board of Directors (the Board"). The Company's current failure to comply with the Audit Committee Composition Requirement is due to a vacancy resulting from Alan Edrick's resignation from the Board and the Audit Committee effective June 10, 2025. The Company intends to regain compliance with Nasdaq Listing Rule 5605(c)(2)(A) by appointing a new Board member who meets the independence requirements under Nasdaq rules and Rule 10A-3(b)(1) under the Securities Exchange Act of 1934, as amended, as expeditiously as practicable. Until such appointment, the Company plans to rely on the cure period set in Nasdaq Listing Rule 5605(c)(4), which gives the Company until the earlier of (i) the Company's next annual meeting of stockholders or (ii) one year from Mr. Edrick's resignation, or June 10, 2026 to satisfy the Audit Committee Composition Requirement.お知らせ • Jun 03Harvard Bioscience, Inc. Announces Board and Committee ChangesOn May 30, 2025, Thomas Loewald informed the Company of his resignation from the board of directors of Harvard Bioscience, Inc., effective May 30, 2025. Mr. Loewald has been a director since October 2017. On June 2, 2025, the Board appointed John Duke to its board of directors, effective June 2, 2025. Mr. Duke will also serve on the audit and nominating and governance committees. The Company also announced that Katherine Eade has been named Lead Independent Director of the Company’s board of directors. Mr. Duke, age 54, currently serves as Chief Executive Officer of Plastic Molding Technology, a leading supplier of plastic components. Prior to joining PMT, Mr. Duke served as Executive Vice President and Chief Business Officer of Lyten, Inc., a manufacturer of advanced materials, and prior to that spent over twenty years in roles of increasing responsibility at Corning Incorporated, including eight years as a leader in Corning’s Life Sciences division. Mr. Duke earned a Bachelor of Science in Materials Science & Engineering from the University of Utah and a Master of Business Administration from Harvard University.分析記事 • May 29Little Excitement Around Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Revenues As Shares Take 26% PoundingTo the annoyance of some shareholders, Harvard Bioscience, Inc. ( NASDAQ:HBIO ) shares are down a considerable 26% in...新しいナラティブ • May 15Expanding SoHo, BTX, And Mesh MEA Will Open New Markets Expansion of SoHo platform and BTX systems could drive revenue growth in industrial and academic markets through broader applications and bioproduction processes. お知らせ • May 12+ 1 more updateHarvard Bioscience, Inc. Reports Impairment for First Quarter of 2025Harvard Bioscience, Inc. reports impairment for First Quarter of 2025. For the quarter, the company reported goodwill impairment of $(48.0) million.お知らせ • May 06Harvard Bioscience, Inc. to Report Q1, 2025 Results on May 12, 2025Harvard Bioscience, Inc. announced that they will report Q1, 2025 results Pre-Market on May 12, 2025分析記事 • May 02Is Now An Opportune Moment To Examine Harvard Bioscience, Inc. (NASDAQ:HBIO)?Harvard Bioscience, Inc. ( NASDAQ:HBIO ), might not be a large cap stock, but it saw significant share price movement...お知らせ • Apr 23Harvard Bioscience, Inc., Annual General Meeting, Jun 02, 2025Harvard Bioscience, Inc., Annual General Meeting, Jun 02, 2025.お知らせ • Apr 17Harvard Bioscience, Inc. Announces Bertrand Loy Not Standing for Re-Election as Lead Independent Director and as Member of the Audit Committee and the Nominating and Governance CommitteeHarvard Bioscience, Inc. announced that on April 10, 2025, Bertrand Loy informed the Company that he will not stand for re-election at the Company’s 2025 Annual Meeting. Mr. Loy’s decision was not a result of any disagreement or any matter relating to the Company’s operations, policies, or practices. Mr. Loy has served as a member of the Board since 2014 and currently serves as the Company’s Lead Independent Director and as a member of the Audit Committee and the Nominating and Governance Committee. Mr. Loy will continue to serve as a director and in such roles until the Company’s 2025 Annual Meeting. The Board expresses its appreciation to Mr. Loy for his service to the Company.お知らせ • Apr 11+ 2 more updatesHarvard Bioscience Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock MarketOn April 4, 2025, Harvard Bioscience, Inc. received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market under Nasdaq Listing Rule 5450(a)(1). Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of thirty (30) consecutive business days. Based on the closing bid price of the Company’s common stock for the thirty (30) consecutive business days from February 21, 2025 to April 3, 2025, the Company no longer meets the minimum bid price requirement. The Notification Letter does not impact the Company’s listing on The Nasdaq Global Market at this time. The Notification Letter states that the Company has 180 calendar days, or until October 1, 2025, to regain compliance with Nasdaq Listing Rule 5450(a)(1). To regain compliance, the bid price of the Company’s common stock must have a closing bid price of at least $1.00 per share for a minimum of ten (10) consecutive business days. If the Company does not regain compliance with Nasdaq Listing Rule 5450(a)(1) by October 1, 2025, the Company may be eligible to transfer from the Nasdaq Global Market to the Nasdaq Capital Market and seek an additional 180 calendar day compliance period. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and would need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. However, if it appears to the staff of Nasdaq (the “Staff”) that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq would notify the Company that its securities would be subject to delisting. In the event of such a notification, the Company may appeal the Staff’s determination to delist its securities, but there can be no assurance the Staff would grant the Company’s request for continued listing.分析記事 • Apr 11Lacklustre Performance Is Driving Harvard Bioscience, Inc.'s (NASDAQ:HBIO) 49% Price DropTo the annoyance of some shareholders, Harvard Bioscience, Inc. ( NASDAQ:HBIO ) shares are down a considerable 49% in...お知らせ • Mar 12Harvard Bioscience, Inc. Provides Earnings Guidance for the First Quarter of 2025Harvard Bioscience, Inc. provided earnings guidance for the first quarter of 2025. For the quarter, the company expects revenues to be between $19 million to $21 million.お知らせ • Feb 25+ 1 more updateHarvard Bioscience, Inc. to Showcase Latest Solutions for Preclinical and Organoid Applications at Society of Toxicology MeetingHarvard Bioscience, Inc. announced that it will be showcasing its latest product innovations at the Society of Toxicology (SOT) conference from March 17-20, 2025, in Orlando. Building upon its comprehensive product portfolio, these latest developments open promising new avenues for progressing preclinical research and organoid-based therapeutic development. Expansion of SoHo™ Implantable Real-Time Telemetry Platform: The SoHo telemetry solution enables researchers to collect, manage, analyze and report findings from multiple concurrent small animal models in both shared housing and extended range environments. The Company will unveil its newly launched SoHo biopotential monitoring devices used in many study types including neurotoxicity and cardiovascular toxicology studies. The SoHo telemetry platform integrates with the Company's GLP-compliant Ponemah data management platform which automates data collection, analysis, and reporting, to reduce manual effort and improve consistency in results. The system supports the customer's business needs by reducing operating costs and test cycle times, enabling increased testing throughput and possibilities for emerging AI-based analysis of preclinical datasets. The Company to Present on VivaMARS Activity Monitoring System: Powered by Ponemah, the VivaMARS system delivers a comprehensive, GLP-compliant platform for precise, real-time behavioral analysis. This integrated solution addresses the demands of CROs and pharmaceutical companies to reduce cycle times and increase revenue streams, especially with neuropharmacology and neurotoxicology applications. Multi Channel Systems Mesh MEA™ Organoid Platform: The Company will also be highlighting its innovative Mesh Microelectrode Array (MEA) platform, specifically engineered for organoid applications. Building upon its established expertise in vitro MEA technology, this Mesh MEA™ system enables scientists to obtain detailed, real-time electrophysiological readings from within living organoids. This advanced platform has been purposefully developed to support the growing demand of organoid usage across research and discovery, as well as safety pharmacology and toxicology studies.分析記事 • Feb 07Harvard Bioscience, Inc. (NASDAQ:HBIO) Looks Inexpensive After Falling 31% But Perhaps Not Attractive EnoughUnfortunately for some shareholders, the Harvard Bioscience, Inc. ( NASDAQ:HBIO ) share price has dived 31% in the last...分析記事 • Feb 07Why Investors Shouldn't Be Surprised By Harvard Bioscience, Inc.'s (NASDAQ:HBIO) 31% Share Price PlungeUnfortunately for some shareholders, the Harvard Bioscience, Inc. ( NASDAQ:HBIO ) share price has dived 31% in the last...お知らせ • Nov 08Harvard Bioscience, Inc. Provides Revenue Guidance for the Fourth Quarter of 2024Harvard Bioscience, Inc. provided revenue guidance for the fourth quarter of 2024. For the quarter, the company expects revenue of $23 million to $26 million.分析記事 • Nov 07Is Now An Opportune Moment To Examine Harvard Bioscience, Inc. (NASDAQ:HBIO)?Harvard Bioscience, Inc. ( NASDAQ:HBIO ), is not the largest company out there, but it saw a significant share price...お知らせ • Oct 03Harvard Bioscience, Inc. to Showcase Innovative Technologies at Society for Neuroscience Annual Meeting 2024Harvard Bioscience, Inc. announced that it will be showcasing its latest product innovations at the Society for Neuroscience (SfN) 2024 Annual Meeting being held October 5 - 9 in Chicago. Cutting-edge innovations on display include the revolutionary new Mesh MEA™ microelectrode array system, the SoHo™ implantable telemetry platform, and the VivaMARS™ activity monitoring system. The Company will exhibit its organoid-centric mesh Microelectrode Array (MEA) platform, which continues to gain traction among the scientific and therapy development communities. Unlike traditional technologies, the new Mesh MEA organoid platform captures electrophysiology signals from inside the organoid in real time, providing researchers with exciting new insights into complex neural dynamics and brain disorders. The Mesh MEA platform is currently being evaluated at select test sites for neurological and cardiac research in addition to safety pharmacology and toxicology applications. The Company has also begun limited quantity shipments to early adopters, with full production expected in the first half of 2025.お知らせ • Sep 18Harvard Bioscience, Inc. to Showcase Latest Solutions for Preclinical and Organoid Applications At Safety Pharmacology Society Annual MeetingHarvard Bioscience, Inc. announced that it will be showcasing its latest product innovations at the Safety Pharmacology Society (SPS) Annual Meeting being held from September 22-25, 2024, in San Diego. SDI™? Ponemah™? Data Management Platform Provides Integrated Preclinical Solution. The Company's Ponemah™? platform, known for its compliance with GLP standards, is a leading tool for managing and analyzing data from a wide range of preclinical studies. Ponemah also enables future use of machine learning algorithms to efficiently analyze large data pools. SoHo™? Implantable Real-Time Telemetry for Small Animal Models: Introduced earlier this year, the Company's SoHo telemetry system is now in use by leading preclinical researchers to support their testing needs. The small footprint of the SoHo telemetry solution allows researchers to carry out studies using a wide range of animal models in high density and more natural shared housing environments. The SoHo system's new power management features create opportunities for longer duration longitudinal studies, and the Ponemah platform integration provides a powerful tool for collecting, managing, analyzing and reporting study data. SoHo supports the customer's business needs by reducing space needs, operating costs and test cycle times, and enabling increased testing throughput. VivaMARS's high level of automation supports the customer's business needs By reducing operating expenses and test cycle time. At SPS, the Company will be presenting a poster authored in cooperation with a leading CRO customer providing initial results with the VivaMARS system. The VivaMARS system represents a fundamental advance in highly automated behavioral testing and is currently available for shipment. MCS™? Mesh MEA™? Organoid Platform: The Company will also be highlighting its considerable progress toward adoption of its organoid-centric mesh Microelectrode Array (MEA) platform. Designed for the emerging applications of organoids in research and discovery, safety pharmacology and toxicology, the new Mesh MEA™? platform allows researchers to capture precise electrophysiology measurements from inside the living organoid in real time. In addition, the Mesh MEA platform is expected to provide an efficient in-vitro screening option designed to reduce large population small model testing.お知らせ • Aug 09Harvard Bioscience, Inc. Provides Revenue Guidance for the Year 2024Harvard Bioscience, Inc. provided revenue guidance for the year 2024. For the year, the company expects revenue outlook to approximately $97 million to $102 million.分析記事 • Aug 07Harvard Bioscience (NASDAQ:HBIO) Is Making Moderate Use Of DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...お知らせ • Aug 02Harvard Bioscience, Inc. to Report Q2, 2024 Results on Aug 08, 2024Harvard Bioscience, Inc. announced that they will report Q2, 2024 results Pre-Market on Aug 08, 2024分析記事 • Jul 15Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares Not Telling The Full StoryYou may think that with a price-to-sales (or "P/S") ratio of 1.3x Harvard Bioscience, Inc. ( NASDAQ:HBIO ) is...お知らせ • May 08Harvard Bioscience, Inc. Provides Earnings Guidance for the Full Year 2024Harvard Bioscience, Inc. provided earnings guidance for the full year 2024. For the full year 2024, the company expects revenues to be approximately flat versus 2023. The company expects second half growth versus both first half of 2024 and second half of 2023, supported by new product commercializations and expected improvements in China.お知らせ • May 01Harvard Bioscience, Inc. to Report Q1, 2024 Results on May 07, 2024Harvard Bioscience, Inc. announced that they will report Q1, 2024 results Pre-Market on May 07, 2024お知らせ • Apr 10Harvard Bioscience, Inc. Announces Action to Improve Operational Efficiency and Support Ongoing Investments in GrowthHarvard Bioscience, Inc. announced a labor force reduction to improve its operating cost structure and support its ongoing investments in growth. The Company expects to realize overall annual run rate savings of approximately $4 million beginning in the second quarter of 2024. The Company also expects second quarter restructuring-related charges of approximately $0.5 million.お知らせ • Apr 04Harvard Bioscience, Inc., Annual General Meeting, May 14, 2024Harvard Bioscience, Inc., Annual General Meeting, May 14, 2024, at 11:00 Eastern Daylight. Agenda: To consider election of one Class III Director named in the accompanying proxy statement, nominated by the Board of Directors for a three-year term, such term to continue until the annual meeting of stockholders in 2027 and until such Director’s successor is duly elected and qualified or until his earlier resignation or removal; to ratify of the appointment of Grant Thornton LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2024; to consider approval, by a non-binding advisory vote, of the compensation of company named executive officers; and to consider Such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof.New Risk • Mar 10New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company.Reported Earnings • Mar 09Full year 2023 earnings: EPS misses analyst expectationsFull year 2023 results: US$0.081 loss per share (improved from US$0.23 loss in FY 2022). Revenue: US$112.3m (down 1.0% from FY 2022). Net loss: US$3.42m (loss narrowed 64% from FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 129%. Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.お知らせ • Mar 07Harvard Bioscience, Inc. Provides Revenue Guidance for the Full Year 2024Harvard Bioscience, Inc. provided revenue guidance for the full year 2024. for the year, The company expects flat to modest revenue growth, also expect strong second half growth versus both first half of 2024 and second half of 2023, supported by new product commercializations and expected improvements in Chinese market conditions.お知らせ • Mar 06Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications At Society of Toxicology MeetingHarvard Bioscience, Inc. announced that it will be showcasing its latest product innovations at the Society of Toxicology (SOT) conference from March 11-13, 2024, in Salt Lake City. Complementing an already extensive product line, the new innovations provide new opportunities for advancing preclinical and organoid-focused therapy development. The Company’s GLP-compliant Ponemah™ preclinical data management platform now includes integrations with the new SoHo™ implantable telemetry solution and the VivaMARS™ high-capacity behavior monitoring system. By integrating these new applications in a single data management platform, the Ponemah system provides users with a powerful tool for managing and analyzing data across a range of studies. The integrated platform also opens new opportunities for the use of emerging machine learning-based algorithms to efficiently analyze large data pools. Together with the Ponemah platform, the SoHo telemetry solution enables researchers to collect, manage, analyze and report findings from multiple concurrent small animal models in a more natural shared housing environment. In addition, the SoHo solution allows data to be collected over longer time periods and opens new opportunities for longitudinal studies. SoHo supports the customer’s business needs by reducing operating costs and test cycle times, enabling increased testing throughput. The VivaMARS system combines the Company’s infrared Panlab® activity monitoring technology with its Ponemah platform to create an integrated, GLP-compliant solution for real-time, high precision behavioral testing. The system is ideally suited to meet the high throughput, automated neuropharmacology and neurotoxicology testing needs of CROs and pharma companies, in addition to longitudinal behavior studies carried out by leading research and academic institutes.お知らせ • Feb 28Harvard Bioscience, Inc. to Report Q4, 2023 Results on Mar 07, 2024Harvard Bioscience, Inc. announced that they will report Q4, 2023 results After-Market on Mar 07, 2024分析記事 • Dec 22Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance CompletelyThe Harvard Bioscience, Inc. ( NASDAQ:HBIO ) share price has done very well over the last month, posting an excellent...Reported Earnings • Nov 09Third quarter 2023 earnings: EPS and revenues miss analyst expectationsThird quarter 2023 results: US$0.029 loss per share (improved from US$0.082 loss in 3Q 2022). Revenue: US$25.4m (down 5.8% from 3Q 2022). Net loss: US$1.24m (loss narrowed 64% from 3Q 2022). Revenue missed analyst estimates by 9.1%. Earnings per share (EPS) also missed analyst estimates by 200%. Revenue is forecast to grow 7.9% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.お知らせ • Nov 08Harvard Bioscience, Inc. Provides Revenue Guidance for the Year 2023Harvard Bioscience, Inc. provided revenue guidance for the year 2023. The company now expect fiscal 2023 revenue to be approximately flat as compared to 2022. Expected 2023 revenue includes an approximately 5% point headwind from discontinued products.お知らせ • Nov 07Harvard Bioscience, Inc. to Showcase Latest Innovations in Preclinical and Organoid Research At Society for Neuroscience ConferenceHarvard Bioscience, Inc. announced that it will be showcasing its latest product innovations at the Society for Neuroscience (SfN) conference from November 12-15, 2023, in Washington, D.C. Complementing an already extensive product line, the new innovations provide exciting new opportunities for advancing preclinical and organoid-focused research and therapy development by a broad range of customers. The latest advancements from the Company's Data Sciences International (DSI) preclinical business expand the reach of DSI's industry-leading, GLP-compliant Ponemah preclinical data management platform. These advancements include DSI's new SoHo implantable telemetry solution for small animal models and its VivaMARS™? high-capacity behavior monitoring system. Integrated with the Ponemah platform, the SoHo implantable real-time telemetry solution enables researchers to collect, manage, analyze and report findings from multiple concurrent small animal models in a more natural shared housing environment. In addition, the SoHo solution allows data to be collected over longer time periods and opens exciting new opportunities for longitudinal studies. The SoHo solution is designed to support the customer's business needs by reducing operating costs and test cycle times, enabling increased testing throughput. The VivaMARS system combines the Company’s real-time high precision Panlab® activity monitoring technology with its Ponemah preclinical data management platform to create an integrated GLP-compliant solution. The system is ideally suited to meet the high throughput, automated neuropharmacology and neurotoxicology testing needs of CROs and pharma companies, in addition to longitudinal behavior studies carried out by leading research and academic institutes. From Multi Channel Systems team, the Company will exhibit its first organoid-centric mesh Microelectrode Array (MEA). Expanding its recognized leadership position in in-vitro MEA products, the new mesh MEA system allows researchers to capture precise electrophysiology measurements from inside the organoid in real time. This new mesh MEA technology is designed for the emerging applications of organoids in research and discovery, safety pharmacology and toxicology. The Company will present early research results using this novel technology in neuroscience studies.お知らせ • Oct 31Harvard Bioscience, Inc. to Report Q3, 2023 Results on Nov 07, 2023Harvard Bioscience, Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 07, 2023分析記事 • Sep 23Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share PriceKey Insights Using the 2 Stage Free Cash Flow to Equity, Harvard Bioscience fair value estimate is US$6.55 Current...Recent Insider Transactions • Aug 24President recently bought US$110k worth of stockOn the 17th of August, James Green bought around 25k shares on-market at roughly US$4.38 per share. This transaction amounted to 1.6% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. James has been a buyer over the last 12 months, purchasing a net total of US$290k worth in shares.分析記事 • Aug 10Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some ScrutinyThe Harvard Bioscience, Inc. ( NASDAQ:HBIO ) share price has fared very poorly over the last month, falling by a...New Risk • Aug 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company.お知らせ • Aug 09Harvard Bioscience, Inc. Provides Earnings Guidance for Full Year 2023Harvard Bioscience, Inc. provided earnings guidance for full year 2023. For the year, the company expects revenues of approximately $116 million to $120 million.Buying Opportunity • Aug 09Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 23%. The fair value is estimated to be US$5.65, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.3% over the last 3 years. Earnings per share has grown by 12%.Reported Earnings • Aug 08Second quarter 2023 earnings: EPS and revenues miss analyst expectationsSecond quarter 2023 results: US$0.023 loss per share (down from US$0.059 profit in 2Q 2022). Revenue: US$28.8m (down 1.5% from 2Q 2022). Net loss: US$980.0k (down 140% from profit in 2Q 2022). Revenue missed analyst estimates by 2.5%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 8.5% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.お知らせ • Jul 29Harvard Bioscience, Inc. to Report Q2, 2023 Results on Aug 08, 2023Harvard Bioscience, Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 08, 2023Buying Opportunity • Jul 07Now 20% undervaluedOver the last 90 days, the stock is up 30%. The fair value is estimated to be US$6.93, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.2% over the last 3 years. Earnings per share has grown by 17%.お知らせ • Jun 21Harvard Bioscience, Inc. Appoints Jennifer Cote as Chief Financial OfficerHarvard Bioscience, Inc. announced the appointment of Jennifer Cote as the Company's Chief Financial Officer, effective June 19, 2023. Cote joined the Company as Vice President of Global Finance in May 2022 and has served as Interim Chief Financial Officer and Treasurer since January 2023. Prior to joining Harvard Bioscience, Cote held various financial, strategy, and operating roles of increasing responsibility at Bose Corporation, a leading supplier of speakers, headphones, electronics and other related products for the consumer audio, automotive, health, and professional audio market. During her tenure at Bose, she led various teams as Head of Strategy Enablement and Finance Services for Boses Global Business Services organization, Head of Finance for Boses Headphones Business Unit, and Head of Global Business Operations and Head of Finance for Boses Professional Systems Division. Earlier in her career, Ms. Cote held various positions of increasing responsibility, including Audit Manager, at Arthur Andersen LLP. A Certified Public Accountant and Chartered Global Management Accountant, Cote holds a Bachelor of Science in Accountancy from Villanova University.分析記事 • Apr 26An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% UndervaluedKey Insights Using the 2 Stage Free Cash Flow to Equity, Harvard Bioscience fair value estimate is US$6.84 Harvard...分析記事 • Apr 11Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Recent Insider Transactions • Mar 21President recently bought US$105k worth of stockOn the 15th of March, James Green bought around 40k shares on-market at roughly US$2.64 per share. This transaction amounted to 2.7% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. James has been a buyer over the last 12 months, purchasing a net total of US$567k worth in shares.Breakeven Date Change • Mar 12Forecast breakeven date moved forward to 2023The 2 analysts covering Harvard Bioscience previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of US$500.0k in 2023. Earnings growth of 104% is required to achieve expected profit on schedule.Reported Earnings • Mar 10Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2022 results: US$0.23 loss per share (further deteriorated from US$0.007 loss in FY 2021). Revenue: US$113.3m (down 4.7% from FY 2021). Net loss: US$9.52m (loss widened US$9.23m from FY 2021). Revenue missed analyst estimates by 1.5%. Earnings per share (EPS) exceeded analyst estimates by 13%. Revenue is forecast to grow 8.5% p.a. on average during the next 2 years, compared to a 6.3% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 6% per year.Recent Insider Transactions • Dec 04President recently bought US$75k worth of stockOn the 1st of December, James Green bought around 30k shares on-market at roughly US$2.51 per share. This transaction amounted to 2.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. James has been a buyer over the last 12 months, purchasing a net total of US$462k worth in shares.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Independent Director Alan Edrick was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.株主還元HBIOUS Life SciencesUS 市場7D11.8%3.2%1.1%1Y66.3%8.3%28.7%株主還元を見る業界別リターン: HBIO過去 1 年間で8.3 % の収益を上げたUS Life Sciences業界を上回りました。リターン対市場: HBIO過去 1 年間で28.7 % の収益を上げたUS市場を上回りました。価格変動Is HBIO's price volatile compared to industry and market?HBIO volatilityHBIO Average Weekly Movement14.6%Life Sciences Industry Average Movement8.1%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%安定した株価: HBIOの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: HBIOの 週次ボラティリティ は過去 1 年間で25%から15%に減少しましたが、依然としてUS株の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1901328John Dukewww.harvardbioscience.comハーバード・バイオサイエンス社は、米州、欧州、中東、アフリカ、アジア、および国際的にライフサイエンス用途の技術、製品、サービスを開発、製造、販売している。同社は、シリンジや蠕動輸液ポンプ製品などの細胞・分子テクノロジー製品、エレクトロポレーションや電気融合装置、アミノ酸分析装置、分光光度計などの分子レベルの試験・研究用機器、細胞分析用データ収集システム、生体内記録用マイクロ電極アレイ・ソリューション一式、細胞外記録用in vitroシステムなどの精密科学計測機器・装置を提供している。前臨床製品としては、研究用生物の生理学的データを評価するプラットフォーム、創薬、創薬開発サービスを提供しており、心臓血管系、中枢神経系、呼吸器系、代謝系データを収集するための研究用埋め込み型および外部装着型テレメトリーシステム、行動学的製品などがある；単離臓器および外科製品、組織・臓器ベースの研究用器具および付属品（外科製品、輸液システム、行動研究システムを含む）、プレチスモグラフチャンバー、データ収集ハードウェア、生理学的信号解析ソフトウェア、最終レポート作成を含むターンキー呼吸器系ソリューション、吸入・曝露システム、GLP対応データ収集・解析システム。同社はウェブサイトや販売代理店を通じて、製薬会社やバイオテクノロジー企業、大学、病院、政府研究所の研究者、契約研究機関や学術研究機関に製品を販売している。主にHarvard Apparatus、Biochrom、BTX、HEKA、KD Scientific、MCS、Warner、DSI、Panlab、Hugo Sachs、Buxcoのブランドで製品を販売している。ハーバード・バイオサイエンス社は1901年に設立され、マサチューセッツ州ホリストンに本拠を置く。もっと見るHarvard Bioscience, Inc. 基礎のまとめHarvard Bioscience の収益と売上を時価総額と比較するとどうか。HBIO 基礎統計学時価総額US$25.21m収益（TTM）-US$9.78m売上高(TTM)US$85.53m0.3xP/Sレシオ-2.6xPER（株価収益率HBIO は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計HBIO 損益計算書（TTM）収益US$85.53m売上原価US$35.56m売上総利益US$49.97mその他の費用US$59.75m収益-US$9.78m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-2.17グロス・マージン58.42%純利益率-11.44%有利子負債／自己資本比率360.5%HBIO の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 10:47終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Harvard Bioscience, Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関Raymond MyersBenchmark CompanyBruce JacksonBenchmark CompanyPaul KnightBrean Capital Historical (Janney Montgomery)3 その他のアナリストを表示
Major Estimate Revision • May 19Consensus EPS estimates upgraded to US$1.96 lossThe consensus outlook for fiscal year 2026 has been updated. 2026 losses forecast to reduce from -US$2.45 to -US$1.96 per share. Revenue forecast steady at US$88.6m. Life Sciences industry in the US expected to see average net income growth of 14% next year. Consensus price target of US$6.00 unchanged from last update. Share price fell 7.4% to US$5.01 over the past week.
Breakeven Date Change • May 14No longer forecast to breakevenThe 2 analysts covering Harvard Bioscience no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.60m in 2027. New consensus forecast suggests the company will make a loss of US$2.05m in 2027.
お知らせ • May 14Harvard Bioscience, Inc. Provides Earnings Guidance for the Second Quarter 2026 and Reaffirms Earnings Guidance for the Full Year 2026Harvard Bioscience, Inc. provided earnings guidance for the second quarter 2026 and reaffirmed earnings guidance for the full year 2026. For the quarter, the company expects Revenue between $20.5 million and $22.5 million. The Company’s second quarter outlook reflects year-over-year revenue growth in the mid-single digit range at the midpoint of guidance. The Company is reaffirming its full-year guidance and anticipates a ramp in revenue in the second half of the year, driven by expected sales growth in higher margin NPI pipeline, which includes products for organoids and electroporation. The Company continues to expect Revenue growth between 2% and 4%.
Reported Earnings • May 13First quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2026 results: US$0.77 loss per share (improved from US$11.42 loss in 1Q 2025). Revenue: US$20.8m (down 4.7% from 1Q 2025). Net loss: US$3.42m (loss narrowed 93% from 1Q 2025). Revenue missed analyst estimates by 2.1%. Earnings per share (EPS) exceeded analyst estimates by 19%. Revenue is forecast to grow 1.9% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 19 percentage points per year, which is a significant difference in performance.
New Risk • May 12New major risk - Revenue and earnings growthEarnings have declined by 63% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 63% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable next year (US$17m net loss next year). Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (US$30.8m market cap).
分析記事 • May 07When Should You Buy Harvard Bioscience, Inc. (NASDAQ:HBIO)?Harvard Bioscience, Inc. ( NASDAQ:HBIO ), is not the largest company out there, but it led the NASDAQCM gainers with a...
Major Estimate Revision • May 19Consensus EPS estimates upgraded to US$1.96 lossThe consensus outlook for fiscal year 2026 has been updated. 2026 losses forecast to reduce from -US$2.45 to -US$1.96 per share. Revenue forecast steady at US$88.6m. Life Sciences industry in the US expected to see average net income growth of 14% next year. Consensus price target of US$6.00 unchanged from last update. Share price fell 7.4% to US$5.01 over the past week.
Breakeven Date Change • May 14No longer forecast to breakevenThe 2 analysts covering Harvard Bioscience no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.60m in 2027. New consensus forecast suggests the company will make a loss of US$2.05m in 2027.
お知らせ • May 14Harvard Bioscience, Inc. Provides Earnings Guidance for the Second Quarter 2026 and Reaffirms Earnings Guidance for the Full Year 2026Harvard Bioscience, Inc. provided earnings guidance for the second quarter 2026 and reaffirmed earnings guidance for the full year 2026. For the quarter, the company expects Revenue between $20.5 million and $22.5 million. The Company’s second quarter outlook reflects year-over-year revenue growth in the mid-single digit range at the midpoint of guidance. The Company is reaffirming its full-year guidance and anticipates a ramp in revenue in the second half of the year, driven by expected sales growth in higher margin NPI pipeline, which includes products for organoids and electroporation. The Company continues to expect Revenue growth between 2% and 4%.
Reported Earnings • May 13First quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2026 results: US$0.77 loss per share (improved from US$11.42 loss in 1Q 2025). Revenue: US$20.8m (down 4.7% from 1Q 2025). Net loss: US$3.42m (loss narrowed 93% from 1Q 2025). Revenue missed analyst estimates by 2.1%. Earnings per share (EPS) exceeded analyst estimates by 19%. Revenue is forecast to grow 1.9% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 19 percentage points per year, which is a significant difference in performance.
New Risk • May 12New major risk - Revenue and earnings growthEarnings have declined by 63% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 63% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable next year (US$17m net loss next year). Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (US$30.8m market cap).
分析記事 • May 07When Should You Buy Harvard Bioscience, Inc. (NASDAQ:HBIO)?Harvard Bioscience, Inc. ( NASDAQ:HBIO ), is not the largest company out there, but it led the NASDAQCM gainers with a...
ナラティブの更新 • Apr 30HBIO: Reverse Split And 2026 Outlook Will Frame Balanced Risk RewardNarrative Update: Harvard Bioscience Analysts have reset Harvard Bioscience's price target to $6.00 from $0.60, aligning with the recent 1:10 reverse split and updated revenue expectations for 2026. Analyst Commentary Recent commentary around Harvard Bioscience focuses on how the reverse split and updated 2026 revenue expectations feed into valuation and execution risk.
Board Change • Apr 29High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. 1 highly experienced director. Lead Independent Director Katherine Eade is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Apr 29Harvard Bioscience, Inc. to Report Q1, 2026 Results on May 12, 2026Harvard Bioscience, Inc. announced that they will report Q1, 2026 results Pre-Market on May 12, 2026
お知らせ • Apr 22Harvard Bioscience, Inc., Annual General Meeting, Jun 02, 2026Harvard Bioscience, Inc., Annual General Meeting, Jun 02, 2026.
ナラティブの更新 • Apr 12HBIO: Reverse Split And Cost Savings Plan Will Support Future Upside PotentialNarrative Update Analysts have reset their price target on Harvard Bioscience to $6, largely reflecting the recent 1:10 reverse split and the updated revenue expectations in their models. Analyst Commentary Recent research updates on Harvard Bioscience focus on the technical impact of the 1:10 reverse split and revised revenue assumptions, rather than any major shift in the underlying story.
ナラティブの更新 • Mar 29HBIO: Reverse Split And Cost Savings Program Will Support Future Recovery PotentialAnalysts have reset their price target for Harvard Bioscience from $0.60 to $6.00, reflecting the recent 1 for 10 reverse split and updated modeling rather than a change in the underlying view on the business. Analyst Commentary Recent research updates on Harvard Bioscience have focused on recalibrating models and targets to reflect the 1 for 10 reverse split and revised revenue expectations, rather than a wholesale change in long term conviction.
ナラティブの更新 • Mar 15HBIO: Reset Expectations And Manufacturing Shift Will Set Up Recovery PotentialAnalysts have cut their price target on Harvard Bioscience from $2.00 to $0.60, citing a reduced 2026 revenue estimate of $89.2m versus $95.6m previously and stating that the timing of any recovery is still hard to pinpoint. Analyst Commentary Recent commentary around Harvard Bioscience is focused squarely on the reset to expectations and what it could imply for the share price and business execution over the next few years.
お知らせ • Mar 13Harvard Bioscience, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2026Harvard Bioscience, Inc. provided earnings guidance for the First Quarter and Full Year 2026. For the quarter, the Company expects Revenue between $20.0 million and $22.0 million. For the full year, the Company expects Revenue growth between 2% and 4%.
お知らせ • Feb 26Harvard Bioscience, Inc. to Report Q4, 2025 Results on Mar 12, 2026Harvard Bioscience, Inc. announced that they will report Q4, 2025 results Pre-Market on Mar 12, 2026
お知らせ • Jan 30Harvard Bioscience, Inc. Announces Strategic Consolidation of Manufacturing Operations to Improve Efficiency and Support Long-Term GrowthHarvard Bioscience, Inc. announced a strategic consolidation of its manufacturing operations designed to enhance operational efficiency, strengthen execution, and accelerate cost-savings efforts. The Company will close its manufacturing facility in Holliston, MA and transition U.S. production to its manufacturing hub in Minneapolis, MN. Certain operations will also be relocated to facilities in Germany, Sweden, and the UK, aligning specific product lines with their designated center of excellence and most strategically advantageous logistical location. The Holliston facility will remain operational throughout 2026 to support continuity and customer service. The consolidation is expected to be completed by the first quarter of 2027. The Company has implemented a comprehensive, phased transition plan designed to prevent any disruption to order fulfillment, product quality, and technical support. Transition-related costs are expected to generate incremental operating expenses throughout 2026 and in the first half of 2027. This initiative is expected to result in approximately $3 million in cost savings in 2027, and once fully implemented, approximately $4 million in annual cost savings going forward. The savings include reduced overhead, SKU rationalization, improved asset utilization, and a targeted reconfiguration of the Company's workforce across impacted operations. The Company has also filed a Current Report on Form 8-K with the U.S. Securities and Exchange Commission containing additional details regarding the consolidation of operations.
New Risk • Dec 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$15m net loss next year). Market cap is less than US$100m (US$31.2m market cap).
お知らせ • Dec 17+ 1 more updateHarvard Bioscience, Inc. announced that it expects to receive $40 million in funding from BroadOak Capital Partners, LLCHarvard Bioscience, Inc. announced that it has entered into an agreement with new lender, BroadOak Capital Partners, LLC to provide a $40 million credit facility comprised of three term loans, all of which will be funded on December 17, 2025. The Loan Agreement provides for the following term loans: (i) a term loan in an aggregate principal amount of $10.0 million (the “Term A Loan”), (ii) a term loan in an aggregate principal amount of $22.5 million (the “Term B Loan”) and (iii) a term loan in an aggregate principal amount of $7.5 million (the “Term C Loan” and, together with the Term A Loan and Term B Loan, the “Term Loans”). The Term A Loan and Term B Loan are senior secured obligations maturing on December 17, 2029.
分析記事 • Dec 04Further Upside For Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Could Introduce Price Risks After 27% BounceHarvard Bioscience, Inc. ( NASDAQ:HBIO ) shares have continued their recent momentum with a 27% gain in the last month...
お知らせ • Nov 07Harvard Bioscience, Inc. Provides Earnings Guidance for the Fourth Quarter of 2025Harvard Bioscience, Inc. provided earnings guidance for the fourth quarter of 2025. For the quarter, the Company expects revenues of $22.5 million to $24.5 million and gross margin in the 58% to 60% range.
Reported Earnings • Nov 07Third quarter 2025 earnings: EPS and revenues exceed analyst expectationsThird quarter 2025 results: US$0.028 loss per share (improved from US$0.11 loss in 3Q 2024). Revenue: US$20.6m (down 6.3% from 3Q 2024). Net loss: US$1.23m (loss narrowed 74% from 3Q 2024). Revenue exceeded analyst estimates by 3.0%. Earnings per share (EPS) also surpassed analyst estimates by 50%. Revenue is forecast to grow 5.0% p.a. on average during the next 2 years, compared to a 6.3% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 53 percentage points per year, which is a significant difference in performance.
お知らせ • Oct 30Harvard Bioscience, Inc. to Report Q3, 2025 Results on Nov 06, 2025Harvard Bioscience, Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 06, 2025
分析記事 • Oct 20Harvard Bioscience, Inc. (NASDAQ:HBIO) Looks Inexpensive But Perhaps Not Attractive EnoughHarvard Bioscience, Inc.'s ( NASDAQ:HBIO ) price-to-sales (or "P/S") ratio of 0.2x might make it look like a strong buy...
Price Target Changed • Oct 06Price target decreased by 33% to US$2.00Down from US$3.00, the current price target is provided by 1 analyst. New target price is 355% above last closing price of US$0.44. Stock is down 82% over the past year. The company is forecast to post a net loss per share of US$1.26 next year compared to a net loss per share of US$0.28 last year.
Board Change • Oct 06Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. 1 independent director (4 non-independent directors). Lead Independent Director Katherine Eade is the most experienced director on the board, commencing their role in 2017. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.
お知らせ • Oct 04Harvard Bioscience Receives a Notification Letter from the Listing Qualifications Department of the Nasdaq Stock MarketOn October 2, 2025, Harvard Bioscience, Inc., received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it had been granted an additional 180 days, or until March 30, 2026, to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”), based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market with the exception of the bid price requirement, and the Company’s written notice of its intention to cure the deficiency during the second compliance period. In order to be eligible to receive the Second Compliance Period, the Company applied to have its common stock transferred from the Nasdaq Global Market to the Nasdaq Capital Market. In connection with the grant of the Second Compliance Period, the application was approved and the Common Stock will move to the Nasdaq Capital Market effective at the opening of business on October 3, 2025. If at any time before March 30, 2026, the bid price of the Common Stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, the Staff will provide written confirmation that the Company has achieved compliance, subject to the Staff’s discretion to extend the minimum bid price compliance period. If the Company does not regain compliance with the Minimum Bid Price Requirement by the end of the Second Compliance Period, the Common Stock will become subject to delisting. In the event that the Company receives notice that the Common Stock is being delisted, the Nasdaq listing rules permit the Company to appeal a delisting determination by the Staff to a hearings panel. The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Market, and the Company’s Common Stock will continue to be listed and traded under the symbol “HBIO.” The Company intends to continue to monitor the closing bid price of the Common Stock between now and March 30, 2026, and will consider available options to regain compliance with the Minimum Bid Price Requirement, including effecting a reverse stock split, if necessary. However, there can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement or will otherwise be in compliance with other Nasdaq Listing Rules.
ナラティブの更新 • Sep 11Demographic Shifts And NIH Funding Will Unlock Biomedical PotentialAnalysts have lowered Harvard Bioscience’s price target from $3.00 to $2.00 due to increased uncertainty around research funding, drug pricing pressures, tariff risks, and a generally more cautious sector outlook. Analyst Commentary Uncertainty surrounding basic research funding potentially impacting sector performance.
お知らせ • Sep 09Harvard Bioscience, Inc. Appoints Stephen Denelsky to Board of Directors and as Member of Nominating & Governance Committee, Effective September 5, 2025On September 5, 2025, the Board of Directors of Harvard Bioscience, Inc. appointed Stephen DeNelsky to serve as a member of the Board, effective September 5, 2025. Mr. DeNelsky will serve as a Class I director with a term that will expire at the Company’s 2028 annual meeting of stockholders. Mr. DeNelsky was also appointed to serve as a member of the Nominating & Governance Committee of the Board. Mr. DeNelsky, age 57, is a Managing Director at Oaktree Capital Management, a position he has held since 2022. Mr. DeNelsky was previously a Managing Director at Marathon Asset Management from 2019 to 2022 and President at Life Sciences Alternative Funding from 2011 to 2019. Mr. DeNelsky also currently serves on the board of directors of Visioncare Inc. and previously served on the boards of Integrated Diagnostics and AMICAS, Inc. Mr. DeNelsky possesses thirty years of experience in the research, analysis, and valuation of public and private equities in the healthcare industry and has worked across several major sub-sectors of healthcare, including life sciences, pharmaceuticals, devices and services. Mr. DeNelsky earned his B.A. in Economics from the American University and his M.B.A. from the University of Maryland.
分析記事 • Aug 14Harvard Bioscience, Inc. (NASDAQ:HBIO) Just Reported, And Analysts Assigned A US$3.00 Price TargetNasdaqGM:HBIO 1 Year Share Price vs Fair Value Explore Harvard Bioscience's Fair Values from the Community and select...
お知らせ • Aug 12Harvard Bioscience, Inc. Provides Earnings Guidance for the Third Quarter Ending September 30, 2025Harvard Bioscience, Inc. provided earnings guidance for the third quarter ending September 30, 2025. For the quarter, the Company expects third quarter 2025 revenues of $19 million to $21 million.
分析記事 • Jul 23Does Harvard Bioscience (NASDAQ:HBIO) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
お知らせ • Jul 17+ 3 more updatesHarvard Bioscience, Inc. to Report Q2, 2025 Results on Aug 11, 2025Harvard Bioscience, Inc. announced that they will report Q2, 2025 results on Aug 11, 2025
お知らせ • Jun 29Harvard Bioscience, Inc. Provides Non-Compliance UpdateOn June 18, 2025, Harvard Bioscience, Inc. (the Company") notified the Nasdaq Stock Market LLC (Nasdaq") that the Company is not in compliance with the audit committee requirement set in Nasdaq Listing Rule 5605(c)(2)(A) (the Audit Committee Composition Requirement") due to the Company having only two members on the audit committee (the Audit Committee") of its Board of Directors (the Board"). The Company's current failure to comply with the Audit Committee Composition Requirement is due to a vacancy resulting from Alan Edrick's resignation from the Board and the Audit Committee effective June 10, 2025. On June 26, 2025, the Company received a letter from the staff at the Listing Qualifications Department of Nasdaq (the "Staff") notifying the Company that the Staff had determined that the Company no longer complies with the Audit Committee Composition Requirement. The Company intends to regain compliance with Nasdaq Listing Rule 5605(c)(2)(A) by appointing a new Board member who meets the independence requirements under Nasdaq rules and Rule 10A-3(b)(1) under the Securities Exchange Act of 1934, as amended, as expeditiously as practicable. Until such appointment, the Company plans to rely on the cure period set forth in Nasdaq Listing Rule 5605(c)(4), which gives the Company until the earlier of (i) the Company's next annual meeting of stockholders or (ii) one year from Mr. Edrick's resignation, or June 10, 2026 to satisfy the Audit Committee Composition Requirement.
お知らせ • Jun 24Harvard Bioscience Receives Nasdaq Non-Compliance Notice Regarding Audit Committee RequirementOn June 18, 2025, Harvard Bioscience, Inc. (the Company") notified the Nasdaq Stock Market LLC (Nasdaq") that the Company is not in compliance with the audit committee requirement set in Nasdaq Listing Rule 5605(c)(2)(A) (the Audit Committee Composition Requirement") due to the Company having only two members on the audit committee (the Audit Committee") of its Board of Directors (the Board"). The Company's current failure to comply with the Audit Committee Composition Requirement is due to a vacancy resulting from Alan Edrick's resignation from the Board and the Audit Committee effective June 10, 2025. The Company intends to regain compliance with Nasdaq Listing Rule 5605(c)(2)(A) by appointing a new Board member who meets the independence requirements under Nasdaq rules and Rule 10A-3(b)(1) under the Securities Exchange Act of 1934, as amended, as expeditiously as practicable. Until such appointment, the Company plans to rely on the cure period set in Nasdaq Listing Rule 5605(c)(4), which gives the Company until the earlier of (i) the Company's next annual meeting of stockholders or (ii) one year from Mr. Edrick's resignation, or June 10, 2026 to satisfy the Audit Committee Composition Requirement.
お知らせ • Jun 03Harvard Bioscience, Inc. Announces Board and Committee ChangesOn May 30, 2025, Thomas Loewald informed the Company of his resignation from the board of directors of Harvard Bioscience, Inc., effective May 30, 2025. Mr. Loewald has been a director since October 2017. On June 2, 2025, the Board appointed John Duke to its board of directors, effective June 2, 2025. Mr. Duke will also serve on the audit and nominating and governance committees. The Company also announced that Katherine Eade has been named Lead Independent Director of the Company’s board of directors. Mr. Duke, age 54, currently serves as Chief Executive Officer of Plastic Molding Technology, a leading supplier of plastic components. Prior to joining PMT, Mr. Duke served as Executive Vice President and Chief Business Officer of Lyten, Inc., a manufacturer of advanced materials, and prior to that spent over twenty years in roles of increasing responsibility at Corning Incorporated, including eight years as a leader in Corning’s Life Sciences division. Mr. Duke earned a Bachelor of Science in Materials Science & Engineering from the University of Utah and a Master of Business Administration from Harvard University.
分析記事 • May 29Little Excitement Around Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Revenues As Shares Take 26% PoundingTo the annoyance of some shareholders, Harvard Bioscience, Inc. ( NASDAQ:HBIO ) shares are down a considerable 26% in...
新しいナラティブ • May 15Expanding SoHo, BTX, And Mesh MEA Will Open New Markets Expansion of SoHo platform and BTX systems could drive revenue growth in industrial and academic markets through broader applications and bioproduction processes.
お知らせ • May 12+ 1 more updateHarvard Bioscience, Inc. Reports Impairment for First Quarter of 2025Harvard Bioscience, Inc. reports impairment for First Quarter of 2025. For the quarter, the company reported goodwill impairment of $(48.0) million.
お知らせ • May 06Harvard Bioscience, Inc. to Report Q1, 2025 Results on May 12, 2025Harvard Bioscience, Inc. announced that they will report Q1, 2025 results Pre-Market on May 12, 2025
分析記事 • May 02Is Now An Opportune Moment To Examine Harvard Bioscience, Inc. (NASDAQ:HBIO)?Harvard Bioscience, Inc. ( NASDAQ:HBIO ), might not be a large cap stock, but it saw significant share price movement...
お知らせ • Apr 23Harvard Bioscience, Inc., Annual General Meeting, Jun 02, 2025Harvard Bioscience, Inc., Annual General Meeting, Jun 02, 2025.
お知らせ • Apr 17Harvard Bioscience, Inc. Announces Bertrand Loy Not Standing for Re-Election as Lead Independent Director and as Member of the Audit Committee and the Nominating and Governance CommitteeHarvard Bioscience, Inc. announced that on April 10, 2025, Bertrand Loy informed the Company that he will not stand for re-election at the Company’s 2025 Annual Meeting. Mr. Loy’s decision was not a result of any disagreement or any matter relating to the Company’s operations, policies, or practices. Mr. Loy has served as a member of the Board since 2014 and currently serves as the Company’s Lead Independent Director and as a member of the Audit Committee and the Nominating and Governance Committee. Mr. Loy will continue to serve as a director and in such roles until the Company’s 2025 Annual Meeting. The Board expresses its appreciation to Mr. Loy for his service to the Company.
お知らせ • Apr 11+ 2 more updatesHarvard Bioscience Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock MarketOn April 4, 2025, Harvard Bioscience, Inc. received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market under Nasdaq Listing Rule 5450(a)(1). Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of thirty (30) consecutive business days. Based on the closing bid price of the Company’s common stock for the thirty (30) consecutive business days from February 21, 2025 to April 3, 2025, the Company no longer meets the minimum bid price requirement. The Notification Letter does not impact the Company’s listing on The Nasdaq Global Market at this time. The Notification Letter states that the Company has 180 calendar days, or until October 1, 2025, to regain compliance with Nasdaq Listing Rule 5450(a)(1). To regain compliance, the bid price of the Company’s common stock must have a closing bid price of at least $1.00 per share for a minimum of ten (10) consecutive business days. If the Company does not regain compliance with Nasdaq Listing Rule 5450(a)(1) by October 1, 2025, the Company may be eligible to transfer from the Nasdaq Global Market to the Nasdaq Capital Market and seek an additional 180 calendar day compliance period. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and would need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. However, if it appears to the staff of Nasdaq (the “Staff”) that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq would notify the Company that its securities would be subject to delisting. In the event of such a notification, the Company may appeal the Staff’s determination to delist its securities, but there can be no assurance the Staff would grant the Company’s request for continued listing.
分析記事 • Apr 11Lacklustre Performance Is Driving Harvard Bioscience, Inc.'s (NASDAQ:HBIO) 49% Price DropTo the annoyance of some shareholders, Harvard Bioscience, Inc. ( NASDAQ:HBIO ) shares are down a considerable 49% in...
お知らせ • Mar 12Harvard Bioscience, Inc. Provides Earnings Guidance for the First Quarter of 2025Harvard Bioscience, Inc. provided earnings guidance for the first quarter of 2025. For the quarter, the company expects revenues to be between $19 million to $21 million.
お知らせ • Feb 25+ 1 more updateHarvard Bioscience, Inc. to Showcase Latest Solutions for Preclinical and Organoid Applications at Society of Toxicology MeetingHarvard Bioscience, Inc. announced that it will be showcasing its latest product innovations at the Society of Toxicology (SOT) conference from March 17-20, 2025, in Orlando. Building upon its comprehensive product portfolio, these latest developments open promising new avenues for progressing preclinical research and organoid-based therapeutic development. Expansion of SoHo™ Implantable Real-Time Telemetry Platform: The SoHo telemetry solution enables researchers to collect, manage, analyze and report findings from multiple concurrent small animal models in both shared housing and extended range environments. The Company will unveil its newly launched SoHo biopotential monitoring devices used in many study types including neurotoxicity and cardiovascular toxicology studies. The SoHo telemetry platform integrates with the Company's GLP-compliant Ponemah data management platform which automates data collection, analysis, and reporting, to reduce manual effort and improve consistency in results. The system supports the customer's business needs by reducing operating costs and test cycle times, enabling increased testing throughput and possibilities for emerging AI-based analysis of preclinical datasets. The Company to Present on VivaMARS Activity Monitoring System: Powered by Ponemah, the VivaMARS system delivers a comprehensive, GLP-compliant platform for precise, real-time behavioral analysis. This integrated solution addresses the demands of CROs and pharmaceutical companies to reduce cycle times and increase revenue streams, especially with neuropharmacology and neurotoxicology applications. Multi Channel Systems Mesh MEA™ Organoid Platform: The Company will also be highlighting its innovative Mesh Microelectrode Array (MEA) platform, specifically engineered for organoid applications. Building upon its established expertise in vitro MEA technology, this Mesh MEA™ system enables scientists to obtain detailed, real-time electrophysiological readings from within living organoids. This advanced platform has been purposefully developed to support the growing demand of organoid usage across research and discovery, as well as safety pharmacology and toxicology studies.
分析記事 • Feb 07Harvard Bioscience, Inc. (NASDAQ:HBIO) Looks Inexpensive After Falling 31% But Perhaps Not Attractive EnoughUnfortunately for some shareholders, the Harvard Bioscience, Inc. ( NASDAQ:HBIO ) share price has dived 31% in the last...
分析記事 • Feb 07Why Investors Shouldn't Be Surprised By Harvard Bioscience, Inc.'s (NASDAQ:HBIO) 31% Share Price PlungeUnfortunately for some shareholders, the Harvard Bioscience, Inc. ( NASDAQ:HBIO ) share price has dived 31% in the last...
お知らせ • Nov 08Harvard Bioscience, Inc. Provides Revenue Guidance for the Fourth Quarter of 2024Harvard Bioscience, Inc. provided revenue guidance for the fourth quarter of 2024. For the quarter, the company expects revenue of $23 million to $26 million.
分析記事 • Nov 07Is Now An Opportune Moment To Examine Harvard Bioscience, Inc. (NASDAQ:HBIO)?Harvard Bioscience, Inc. ( NASDAQ:HBIO ), is not the largest company out there, but it saw a significant share price...
お知らせ • Oct 03Harvard Bioscience, Inc. to Showcase Innovative Technologies at Society for Neuroscience Annual Meeting 2024Harvard Bioscience, Inc. announced that it will be showcasing its latest product innovations at the Society for Neuroscience (SfN) 2024 Annual Meeting being held October 5 - 9 in Chicago. Cutting-edge innovations on display include the revolutionary new Mesh MEA™ microelectrode array system, the SoHo™ implantable telemetry platform, and the VivaMARS™ activity monitoring system. The Company will exhibit its organoid-centric mesh Microelectrode Array (MEA) platform, which continues to gain traction among the scientific and therapy development communities. Unlike traditional technologies, the new Mesh MEA organoid platform captures electrophysiology signals from inside the organoid in real time, providing researchers with exciting new insights into complex neural dynamics and brain disorders. The Mesh MEA platform is currently being evaluated at select test sites for neurological and cardiac research in addition to safety pharmacology and toxicology applications. The Company has also begun limited quantity shipments to early adopters, with full production expected in the first half of 2025.
お知らせ • Sep 18Harvard Bioscience, Inc. to Showcase Latest Solutions for Preclinical and Organoid Applications At Safety Pharmacology Society Annual MeetingHarvard Bioscience, Inc. announced that it will be showcasing its latest product innovations at the Safety Pharmacology Society (SPS) Annual Meeting being held from September 22-25, 2024, in San Diego. SDI™? Ponemah™? Data Management Platform Provides Integrated Preclinical Solution. The Company's Ponemah™? platform, known for its compliance with GLP standards, is a leading tool for managing and analyzing data from a wide range of preclinical studies. Ponemah also enables future use of machine learning algorithms to efficiently analyze large data pools. SoHo™? Implantable Real-Time Telemetry for Small Animal Models: Introduced earlier this year, the Company's SoHo telemetry system is now in use by leading preclinical researchers to support their testing needs. The small footprint of the SoHo telemetry solution allows researchers to carry out studies using a wide range of animal models in high density and more natural shared housing environments. The SoHo system's new power management features create opportunities for longer duration longitudinal studies, and the Ponemah platform integration provides a powerful tool for collecting, managing, analyzing and reporting study data. SoHo supports the customer's business needs by reducing space needs, operating costs and test cycle times, and enabling increased testing throughput. VivaMARS's high level of automation supports the customer's business needs By reducing operating expenses and test cycle time. At SPS, the Company will be presenting a poster authored in cooperation with a leading CRO customer providing initial results with the VivaMARS system. The VivaMARS system represents a fundamental advance in highly automated behavioral testing and is currently available for shipment. MCS™? Mesh MEA™? Organoid Platform: The Company will also be highlighting its considerable progress toward adoption of its organoid-centric mesh Microelectrode Array (MEA) platform. Designed for the emerging applications of organoids in research and discovery, safety pharmacology and toxicology, the new Mesh MEA™? platform allows researchers to capture precise electrophysiology measurements from inside the living organoid in real time. In addition, the Mesh MEA platform is expected to provide an efficient in-vitro screening option designed to reduce large population small model testing.
お知らせ • Aug 09Harvard Bioscience, Inc. Provides Revenue Guidance for the Year 2024Harvard Bioscience, Inc. provided revenue guidance for the year 2024. For the year, the company expects revenue outlook to approximately $97 million to $102 million.
分析記事 • Aug 07Harvard Bioscience (NASDAQ:HBIO) Is Making Moderate Use Of DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
お知らせ • Aug 02Harvard Bioscience, Inc. to Report Q2, 2024 Results on Aug 08, 2024Harvard Bioscience, Inc. announced that they will report Q2, 2024 results Pre-Market on Aug 08, 2024
分析記事 • Jul 15Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares Not Telling The Full StoryYou may think that with a price-to-sales (or "P/S") ratio of 1.3x Harvard Bioscience, Inc. ( NASDAQ:HBIO ) is...
お知らせ • May 08Harvard Bioscience, Inc. Provides Earnings Guidance for the Full Year 2024Harvard Bioscience, Inc. provided earnings guidance for the full year 2024. For the full year 2024, the company expects revenues to be approximately flat versus 2023. The company expects second half growth versus both first half of 2024 and second half of 2023, supported by new product commercializations and expected improvements in China.
お知らせ • May 01Harvard Bioscience, Inc. to Report Q1, 2024 Results on May 07, 2024Harvard Bioscience, Inc. announced that they will report Q1, 2024 results Pre-Market on May 07, 2024
お知らせ • Apr 10Harvard Bioscience, Inc. Announces Action to Improve Operational Efficiency and Support Ongoing Investments in GrowthHarvard Bioscience, Inc. announced a labor force reduction to improve its operating cost structure and support its ongoing investments in growth. The Company expects to realize overall annual run rate savings of approximately $4 million beginning in the second quarter of 2024. The Company also expects second quarter restructuring-related charges of approximately $0.5 million.
お知らせ • Apr 04Harvard Bioscience, Inc., Annual General Meeting, May 14, 2024Harvard Bioscience, Inc., Annual General Meeting, May 14, 2024, at 11:00 Eastern Daylight. Agenda: To consider election of one Class III Director named in the accompanying proxy statement, nominated by the Board of Directors for a three-year term, such term to continue until the annual meeting of stockholders in 2027 and until such Director’s successor is duly elected and qualified or until his earlier resignation or removal; to ratify of the appointment of Grant Thornton LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2024; to consider approval, by a non-binding advisory vote, of the compensation of company named executive officers; and to consider Such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof.
New Risk • Mar 10New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company.
Reported Earnings • Mar 09Full year 2023 earnings: EPS misses analyst expectationsFull year 2023 results: US$0.081 loss per share (improved from US$0.23 loss in FY 2022). Revenue: US$112.3m (down 1.0% from FY 2022). Net loss: US$3.42m (loss narrowed 64% from FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 129%. Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
お知らせ • Mar 07Harvard Bioscience, Inc. Provides Revenue Guidance for the Full Year 2024Harvard Bioscience, Inc. provided revenue guidance for the full year 2024. for the year, The company expects flat to modest revenue growth, also expect strong second half growth versus both first half of 2024 and second half of 2023, supported by new product commercializations and expected improvements in Chinese market conditions.
お知らせ • Mar 06Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications At Society of Toxicology MeetingHarvard Bioscience, Inc. announced that it will be showcasing its latest product innovations at the Society of Toxicology (SOT) conference from March 11-13, 2024, in Salt Lake City. Complementing an already extensive product line, the new innovations provide new opportunities for advancing preclinical and organoid-focused therapy development. The Company’s GLP-compliant Ponemah™ preclinical data management platform now includes integrations with the new SoHo™ implantable telemetry solution and the VivaMARS™ high-capacity behavior monitoring system. By integrating these new applications in a single data management platform, the Ponemah system provides users with a powerful tool for managing and analyzing data across a range of studies. The integrated platform also opens new opportunities for the use of emerging machine learning-based algorithms to efficiently analyze large data pools. Together with the Ponemah platform, the SoHo telemetry solution enables researchers to collect, manage, analyze and report findings from multiple concurrent small animal models in a more natural shared housing environment. In addition, the SoHo solution allows data to be collected over longer time periods and opens new opportunities for longitudinal studies. SoHo supports the customer’s business needs by reducing operating costs and test cycle times, enabling increased testing throughput. The VivaMARS system combines the Company’s infrared Panlab® activity monitoring technology with its Ponemah platform to create an integrated, GLP-compliant solution for real-time, high precision behavioral testing. The system is ideally suited to meet the high throughput, automated neuropharmacology and neurotoxicology testing needs of CROs and pharma companies, in addition to longitudinal behavior studies carried out by leading research and academic institutes.
お知らせ • Feb 28Harvard Bioscience, Inc. to Report Q4, 2023 Results on Mar 07, 2024Harvard Bioscience, Inc. announced that they will report Q4, 2023 results After-Market on Mar 07, 2024
分析記事 • Dec 22Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance CompletelyThe Harvard Bioscience, Inc. ( NASDAQ:HBIO ) share price has done very well over the last month, posting an excellent...
Reported Earnings • Nov 09Third quarter 2023 earnings: EPS and revenues miss analyst expectationsThird quarter 2023 results: US$0.029 loss per share (improved from US$0.082 loss in 3Q 2022). Revenue: US$25.4m (down 5.8% from 3Q 2022). Net loss: US$1.24m (loss narrowed 64% from 3Q 2022). Revenue missed analyst estimates by 9.1%. Earnings per share (EPS) also missed analyst estimates by 200%. Revenue is forecast to grow 7.9% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
お知らせ • Nov 08Harvard Bioscience, Inc. Provides Revenue Guidance for the Year 2023Harvard Bioscience, Inc. provided revenue guidance for the year 2023. The company now expect fiscal 2023 revenue to be approximately flat as compared to 2022. Expected 2023 revenue includes an approximately 5% point headwind from discontinued products.
お知らせ • Nov 07Harvard Bioscience, Inc. to Showcase Latest Innovations in Preclinical and Organoid Research At Society for Neuroscience ConferenceHarvard Bioscience, Inc. announced that it will be showcasing its latest product innovations at the Society for Neuroscience (SfN) conference from November 12-15, 2023, in Washington, D.C. Complementing an already extensive product line, the new innovations provide exciting new opportunities for advancing preclinical and organoid-focused research and therapy development by a broad range of customers. The latest advancements from the Company's Data Sciences International (DSI) preclinical business expand the reach of DSI's industry-leading, GLP-compliant Ponemah preclinical data management platform. These advancements include DSI's new SoHo implantable telemetry solution for small animal models and its VivaMARS™? high-capacity behavior monitoring system. Integrated with the Ponemah platform, the SoHo implantable real-time telemetry solution enables researchers to collect, manage, analyze and report findings from multiple concurrent small animal models in a more natural shared housing environment. In addition, the SoHo solution allows data to be collected over longer time periods and opens exciting new opportunities for longitudinal studies. The SoHo solution is designed to support the customer's business needs by reducing operating costs and test cycle times, enabling increased testing throughput. The VivaMARS system combines the Company’s real-time high precision Panlab® activity monitoring technology with its Ponemah preclinical data management platform to create an integrated GLP-compliant solution. The system is ideally suited to meet the high throughput, automated neuropharmacology and neurotoxicology testing needs of CROs and pharma companies, in addition to longitudinal behavior studies carried out by leading research and academic institutes. From Multi Channel Systems team, the Company will exhibit its first organoid-centric mesh Microelectrode Array (MEA). Expanding its recognized leadership position in in-vitro MEA products, the new mesh MEA system allows researchers to capture precise electrophysiology measurements from inside the organoid in real time. This new mesh MEA technology is designed for the emerging applications of organoids in research and discovery, safety pharmacology and toxicology. The Company will present early research results using this novel technology in neuroscience studies.
お知らせ • Oct 31Harvard Bioscience, Inc. to Report Q3, 2023 Results on Nov 07, 2023Harvard Bioscience, Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 07, 2023
分析記事 • Sep 23Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share PriceKey Insights Using the 2 Stage Free Cash Flow to Equity, Harvard Bioscience fair value estimate is US$6.55 Current...
Recent Insider Transactions • Aug 24President recently bought US$110k worth of stockOn the 17th of August, James Green bought around 25k shares on-market at roughly US$4.38 per share. This transaction amounted to 1.6% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. James has been a buyer over the last 12 months, purchasing a net total of US$290k worth in shares.
分析記事 • Aug 10Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some ScrutinyThe Harvard Bioscience, Inc. ( NASDAQ:HBIO ) share price has fared very poorly over the last month, falling by a...
New Risk • Aug 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company.
お知らせ • Aug 09Harvard Bioscience, Inc. Provides Earnings Guidance for Full Year 2023Harvard Bioscience, Inc. provided earnings guidance for full year 2023. For the year, the company expects revenues of approximately $116 million to $120 million.
Buying Opportunity • Aug 09Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 23%. The fair value is estimated to be US$5.65, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.3% over the last 3 years. Earnings per share has grown by 12%.
Reported Earnings • Aug 08Second quarter 2023 earnings: EPS and revenues miss analyst expectationsSecond quarter 2023 results: US$0.023 loss per share (down from US$0.059 profit in 2Q 2022). Revenue: US$28.8m (down 1.5% from 2Q 2022). Net loss: US$980.0k (down 140% from profit in 2Q 2022). Revenue missed analyst estimates by 2.5%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 8.5% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
お知らせ • Jul 29Harvard Bioscience, Inc. to Report Q2, 2023 Results on Aug 08, 2023Harvard Bioscience, Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 08, 2023
Buying Opportunity • Jul 07Now 20% undervaluedOver the last 90 days, the stock is up 30%. The fair value is estimated to be US$6.93, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.2% over the last 3 years. Earnings per share has grown by 17%.
お知らせ • Jun 21Harvard Bioscience, Inc. Appoints Jennifer Cote as Chief Financial OfficerHarvard Bioscience, Inc. announced the appointment of Jennifer Cote as the Company's Chief Financial Officer, effective June 19, 2023. Cote joined the Company as Vice President of Global Finance in May 2022 and has served as Interim Chief Financial Officer and Treasurer since January 2023. Prior to joining Harvard Bioscience, Cote held various financial, strategy, and operating roles of increasing responsibility at Bose Corporation, a leading supplier of speakers, headphones, electronics and other related products for the consumer audio, automotive, health, and professional audio market. During her tenure at Bose, she led various teams as Head of Strategy Enablement and Finance Services for Boses Global Business Services organization, Head of Finance for Boses Headphones Business Unit, and Head of Global Business Operations and Head of Finance for Boses Professional Systems Division. Earlier in her career, Ms. Cote held various positions of increasing responsibility, including Audit Manager, at Arthur Andersen LLP. A Certified Public Accountant and Chartered Global Management Accountant, Cote holds a Bachelor of Science in Accountancy from Villanova University.
分析記事 • Apr 26An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% UndervaluedKey Insights Using the 2 Stage Free Cash Flow to Equity, Harvard Bioscience fair value estimate is US$6.84 Harvard...
分析記事 • Apr 11Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Recent Insider Transactions • Mar 21President recently bought US$105k worth of stockOn the 15th of March, James Green bought around 40k shares on-market at roughly US$2.64 per share. This transaction amounted to 2.7% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. James has been a buyer over the last 12 months, purchasing a net total of US$567k worth in shares.
Breakeven Date Change • Mar 12Forecast breakeven date moved forward to 2023The 2 analysts covering Harvard Bioscience previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of US$500.0k in 2023. Earnings growth of 104% is required to achieve expected profit on schedule.
Reported Earnings • Mar 10Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2022 results: US$0.23 loss per share (further deteriorated from US$0.007 loss in FY 2021). Revenue: US$113.3m (down 4.7% from FY 2021). Net loss: US$9.52m (loss widened US$9.23m from FY 2021). Revenue missed analyst estimates by 1.5%. Earnings per share (EPS) exceeded analyst estimates by 13%. Revenue is forecast to grow 8.5% p.a. on average during the next 2 years, compared to a 6.3% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 6% per year.
Recent Insider Transactions • Dec 04President recently bought US$75k worth of stockOn the 1st of December, James Green bought around 30k shares on-market at roughly US$2.51 per share. This transaction amounted to 2.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. James has been a buyer over the last 12 months, purchasing a net total of US$462k worth in shares.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Independent Director Alan Edrick was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
